|
|
 |
|
Viewing report
|
|
|
|
COPD - Another Reason to Quit
Datamonitor, Dec 2005, Pages: 205
COPD is a deadly disease of the elderly, with patients suffering years of progressive discomfort and disability with no pharmacological interventions able to slow the progressive decline in lung function. A large, increasing patient population demands the development of truly novel COPD-focused therapies which must be coupled with improved disease awareness and diagnosis.
Scope of this title:
- Analysis of diagnosis, epidemiology, and treatment of COPD
- Assessment of the extent to which physicians treat COPD severities differently
- Examination of the use of drug classes and brands across the COPD sub-populations
- Evaluation of future prescribing trends and the potential of novel COPD therapies
Highlights of this title:
Current treatment practice will continue to diverge from international guidelines, with the most important change being the increased use of long-acting bronchodilators in mild COPD.
The use of inhaled corticosteroids will continue to be reserved primarily for late stage disease, until alternative anti-inflammatory agents are available from 2010 onwards.
With no revolutionary new drugs in the pipeline, and novel combinations of existing classes of drugs only offering gains patient compliance, improvements in smoking cessation and pulmonary rehabilitation offer the greatest hope to COPD patients.
Reasons to order your copy:
- Identify the most lucrative target niche populations for developmental products
- Understand how to position new COPD therapies
- Gain insight into prescribing patterns and physician opinion on current treatment paradigms
Customers who bought this item also bought
Commercial Insight: Asthma & COPD - On the verge of generic entry
Commercial Insight: Asthma & COPD - Combination products still have blockbuster potential
Pipeline Insight: Asthma/COPD - Targeted Therapies on the Horizon
Commercial Insight: Asthma and Copd - Combinations breathe life into the asthma and Copd markets
Forecast Insight: Asthma/COPD - Little Long-term Future for Long-acting Single-agent Inhalers?
Asthma & COPD Therapeutics
Asthma And COPD - Get Smart
Commercial Insight: Asthma/COPD - ICS/LABA Combinations Continue to Dominate
Treating COPD Comorbidities: A Market Opportunity for Systemic Anti-Inflammatory Agents?
COPD Drug Discovery: How New Generation Therapies Seek to Target Underlying Disease
Commercial Insight: Asthma and COPD - Control is the Goal
NICE Guidelines on the Management of COPD in Adults in Primary and Secondary Care
|
|
|
|
